Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Shares Outstanding (Weighted Average) (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Shares Outstanding (Weighted Average) for 15 consecutive years, with $6.3 million as the latest value for Q2 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 13.39% to $6.3 million in Q2 2025 year-over-year; TTM through Jun 2025 was $6.3 million, a 13.39% increase, with the full-year FY2025 number at $6.3 million, up 13.39% from a year prior.
  • Shares Outstanding (Weighted Average) was $6.3 million for Q2 2025 at Aytu Biopharma, up from $5.5 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $16.7 million in Q2 2021 to a low of $1.3 million in Q3 2021.
  • A 5-year average of $4.5 million and a median of $3.2 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): skyrocketed 270.57% in 2021, then crashed 91.22% in 2022.
  • Aytu Biopharma's Shares Outstanding (Weighted Average) stood at $1.3 million in 2021, then skyrocketed by 113.38% to $2.8 million in 2022, then surged by 95.17% to $5.5 million in 2023, then rose by 0.69% to $5.5 million in 2024, then increased by 13.39% to $6.3 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Shares Outstanding (Weighted Average) are $6.3 million (Q2 2025), $5.5 million (Q2 2024), and $5.5 million (Q1 2024).